AbbVie Secures Exclusive Rights to RemeGen's RC148, Boosting Oncology Portfolio with $4.95 Billion in Milestone Payments

AbbVie secures a licensing agreement with RemeGen for RC148, a bispecific antibody for advanced solid tumors. RemeGen receives a $650 million upfront payment, with potential milestone payments totaling $4.95 billion. AbbVie plans to explore RC148's potential use with its experimental antibody-drug conjugate, telisotuzumab adizutecan (Temab-A). The deal enhances AbbVie's oncology portfolio and continues its diversification strategy.